NCT04005625

Biotherapy Treatment on Features of Microcrystalline Polyarthritis

Features of Microcrystalline Polyarthritis Treated by Biologics and Evolution - FUMBLE Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 46 (actual)
• Sponsor: University Hospital, Brest · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The study will involve adult patient who had received any biologic agent for microcrystalline disease in western France (Tours, Le Mans, Orléans, Angers, Rennes, Poitiers et Brest) between 01/01/2010 and 31/12/2018. Investigators will answer retrospectively a questionnaire that covers patient and disease data, biologic agent use, efficacy and adverse events.

Detailed description

This is a retrospective multicentric study of all patients treated by biologic for microcrystalline disease in France in western France (Tours, Le Mans, Nantes, La Roche sur Yon, Orléans, Angers, Rennes, Poitiers et Brest) between 01/01/2010 and 31/12/2018. The investigators will collect all clinical (diagnosis of gout CCPD or hydroxyapatitis, tender and swollen joint count), biological (blood results: ESR, CRP, uric acid, synovial analysis), radiological data (X-rays performed and their description) .

Conditions

• Crystal-Induced Arthritis

Timeline

• Start date: 2019-05-01
• Primary completion: 2020-06-01
• Completion: 2020-06-01
• First posted: 2019-07-02
• Last updated: 2020-09-14

Locations

1 site across 1 country: France